But the pipeline contains various approaches that are worth watching, with data from Abbvie possibly the next big event.
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
The world’s largest drug companies splashed out a record $78bn on R&D last year, with Roche and Lilly the biggest spenders.
170 commercial trials were suspended in March while new patient starts slumped 65% as the pandemic swept the globe. April could look even worse.
As Lilly pauses much of its research owing to the coronavirus pandemic, Vantage takes a look at an estimate of the cash committed to ongoing clinical studies. Clue: it’s…
Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.